Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)-Reference-Cited by-同舟云学术

Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder)

Published:2021-05-19 Issue: Volume:18 Page:
ISSN:1570-1638
Container-title:Current Drug Discovery Technologies
language:en
Short-container-title:CDDT

Author:

Ali Faraat¹^ORCID,Sharma Kamna²,Anjum Varisha³^ORCID,Ali Asad⁴^ORCID

Affiliation:

1. Department of Inspection and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority, Plot 112, International Finance Park, Gaborone, Botswana

2. Department of Pharmaceutical Analysis, Indo-Soviet Friendship College of Pharmacy, Moga, Punjab, India

3. Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, India

4. Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard University, New Delhi, India

Abstract

: Inebilizumab-cdon (Uplizna™) was currently approved by the United States Food and Drug Administration (USFDA) for the treatment of NMOSD (neuromyelitis optica spectrum disorder). It was developed by Viela Bio (Nasdaq: VIE) USA. Inebilizumab-cdon (formerly MEDI-551) is a humanized antibody, which induces CD19 + B cell depletion by increasing antibody-dependent cell cytotoxicity (ADCC) and cell phagocytosis (ADCP) of effector cells. Various clinical trials exhibit its safe and effective pharmacokinetic and pharmacodynamic profile. In June 2019, Viela Bio submitted Biologics License Application (BLA) to the FDA based on the findings obtained from the N-Momentum trial. This article summarizes the milestones in the development of Inebilizumab-cdon leading to approval for the treatment of advanced NMOSD.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intruders or protectors – the multifaceted role of B cells in CNS disorders;Frontiers in Cellular Neuroscience;2024-01-10

2. Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report;Frontiers in Neurology;2023-11-21

3. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD;Neurology Neuroimmunology & Neuroinflammation;2023-07

4. B Cell Depletion Therapy as a Cutting-Edge Treatment of Demyelinating Diseases of the Central Nervous System;Annals of Clinical and Experimental Neurology;2023-06-21

5. Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials;Current Drug Targets;2022-07